Received: 19 January 2019
Accepted: 20 March 2019
First Online: 28 March 2019
Ethics approval and consent to participate
: Appropriate consent for reporting patient data presented in this manuscript was obtained at the Dana-Farber Cancer Institute under an institutional review board-approved protocol (DF/HCC protocol #02–180).
: Not applicable.
: MMA: Consultant: Merck, Bristol-Myers Squibb, Genentech, AstraZeneca, Nektar, Ariad. Research Funding: Bristol-Myers Squibb.SD: Consultant: AstraZeneca.AA: Consultant: BP Platform Company.NM: Consultant: Toshiba Medical Systems, WorldCare Clinical, Daiichi Sankyo; Research grant from Merck, Canon Medical Systems, AstraZeneca; Honorarium from Bayer and Roche.LMS: Consultant: Foghorn Therapeutics.Nothing to disclose: BR, SK, SJS, RU.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.